- 5 mg/ml inhalation solution vials (nebulization).

- 90 and 100 ug/spray, aerosol metered (oral inhalation).

Executive Summary

(February 7, 2024)


Albuterol is a short-acting adrenergic β-2 receptor agonist (SABA). It is a fundamental treatment for bronchoconstriction crises typically caused by acute bronchitis, acute asthmatic exacerbations, and acutely decompensated COPD patients (20, 23).

Adult dose for moderate to severe acute bronchoconstriction

Adult dose

Adult dose for moderate to severe acute bronchoconstriction (6, 12, 20)


Adult dose for moderate to severe hyperkalemia (4, 12)

10-20 mg nebulized in 10 minutes . 



Aerosol metered versus nebulized administration


Clinical considerations

Asthma and COPD exacerbation: albuterol role


Severe acute asthmatic exacerbation

Severe acute COPD exacerbation

Hyperkalemia and albuterol

High doses of albuterol can lower potassium serum concentration by 0.5-2 mEq/L (13, 10).

Severe hyperkalemia significance and management overview

Clinical manifestations and ECG changes in hyperkalemia

Albuterol role in hyperkalemia


Albuterol hypersensitivity. No other contraindications have been described. 

Adverse effects

Major drug interactions (22).

Therapeutic ceiling? overdose and lethal dose in animal studies (22) 

Pregnancy and lactation

Pregnancy risk classification

Lactation (7, 19)


® 2023 EMDrugs. All rights reserved.


This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting. 


Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations. 


The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are  affiliated. 


For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.

EMDrugs Team